GENMAB A/S
GNMSFDrugs in Pipeline
17
Phase 3 Programs
11
Upcoming Catalysts
7
Next Catalyst
Oct 2026
Market Overview
Stock performance and key metrics
7 upcoming, 0 past
Epcoritamab
DLBCL
Zalutumumab
Head and Neck Neoplasms
Tisotumab Vedotin
Ovary Cancer
Pegylated liposomal doxorubicin (PLD)
Platinum-resistant Ovarian Cancer
PLD
Platinum-Sensitive Ovarian Cancer
Acasunlimab
PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC
Vincristine
Follicular Lymphoma (FL)
vinorelbine
Cervical Cancer
Rina-S
Non-small Cell Lung Cancer (NSCLC)
Investigator's Choice Chemotherapy
Diffuse Large B-cell Lymphoma
Petosemtamab
Left-sided Colorectal Cancer
HuMax-CD4
Cutaneous T-Cell Lymphoma
Doxorubicin Hydrochloride [HCl]
Non-Hodgkin Lymphoma
Loncastuximab Tesirine
Large B-cell Lymphoma
Investigation agent 2
Relapsed Follicular Lymphoma
GDP
Large Cell Lymphoma, Diffuse
Zanubrutinib
Follicular Lymphoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Epcoritamab | Phase 3 | DLBCL | - | - |
Zalutumumab | Phase 3 | Head and Neck Neoplasms | - | - |
Tisotumab Vedotin | Phase 3 | Ovary Cancer | - | - |
Pegylated liposomal doxorubicin (PLD) | Phase 3 | Platinum-resistant Ovarian Cancer | - | - |
PLD | Phase 3 | Platinum-Sensitive Ovarian Cancer | - | - |
Acasunlimab | Phase 3 | PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC | - | - |
Vincristine | Phase 3 | Follicular Lymphoma (FL) | - | - |
vinorelbine | Phase 3 | Cervical Cancer | - | - |
Rina-S | Phase 3 | Non-small Cell Lung Cancer (NSCLC) | - | - |
Investigator's Choice Chemotherapy | Phase 3 | Diffuse Large B-cell Lymphoma | - | - |
Petosemtamab | Phase 3 | Left-sided Colorectal Cancer | - | - |
HuMax-CD4 | Phase 2 | Cutaneous T-Cell Lymphoma | - | - |
Doxorubicin Hydrochloride [HCl] | Phase 2 | Non-Hodgkin Lymphoma | - | - |
Loncastuximab Tesirine | Phase 2 | Large B-cell Lymphoma | - | - |
Investigation agent 2 | Phase 2 | Relapsed Follicular Lymphoma | - | - |
GDP | Phase 2 | Large Cell Lymphoma, Diffuse | - | - |
Zanubrutinib | Phase 2 | Follicular Lymphoma | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in GENMAB A/S's drug pipeline?→
CatalystAlert tracks 17 drug candidates in GENMAB A/S's (GNMSF) pipeline across Phase 3, Phase 2. Its lead program is Epcoritamab (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is GENMAB A/S's next FDA catalyst?→
GENMAB A/S's (GNMSF) next tracked catalyst is a Phase 2 expected October 1, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track GNMSF biotech catalysts?→
Add GNMSF to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow GENMAB A/S's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.